Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Wolf in Sheep's Clothing: Systemic Immune Activation Post Immunotherapy.
Tiu C, Shinde R, Pal A, Biondo A, Lee A, Tunariu N, Jhanji S, Grover V, Tatham K, Gruber P, Banerji U, De Bono JS, Nicholson E, Minchom AR, Lopez JS. Tiu C, et al. Among authors: minchom ar. J Immunother Precis Oncol. 2021 Sep 7;4(4):189-195. doi: 10.36401/JIPO-21-9. eCollection 2021 Nov. J Immunother Precis Oncol. 2021. PMID: 35665022 Free PMC article. Review.
Multidisciplinary interventions in a specialist Drug Development Unit to improve family history documentation and onward referral of patients with advanced cancer to cancer genetics services.
Moss CA, Cojocaru E, Hanwell J, Ward S, Xu W, van Zyl M, O'Leary L, de Bono JS, Banerji U, Kaye SB, Minchom A, George AJ, Lopez J, McVeigh TP. Moss CA, et al. Eur J Cancer. 2019 Jun;114:97-106. doi: 10.1016/j.ejca.2019.04.009. Epub 2019 May 16. Eur J Cancer. 2019. PMID: 31078974
Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab.
Minchom A, Yuan W, Crespo M, Gurel B, Figueiredo I, Wotherspoon A, Miranda S, Riisnaes R, Ferreira A, Bertan C, Pereira R, Clarke M, Baker C, Ang JE, Fotiadis N, Tunariu N, Carreira S, Popat S, O'Brien M, Banerji U, de Bono J, Lopez J. Minchom A, et al. J Immunother Cancer. 2020 Mar;8(1):e000713. doi: 10.1136/jitc-2020-000713. J Immunother Cancer. 2020. PMID: 32169873 Free PMC article.
Radiological Patterns of Drug-induced Interstitial Lung Disease (DILD) in Early-phase Oncology Clinical Trials.
Terbuch A, Tiu C, Candilejo IM, Scaranti M, Curcean A, Bar D, Estevez Timon M, Ameratunga M, Ang JE, Ratoff J, Minchom AR, Banerji U, de Bono JS, Tunariu N, Lopez JS. Terbuch A, et al. Among authors: minchom ar. Clin Cancer Res. 2020 Sep 15;26(18):4805-4813. doi: 10.1158/1078-0432.CCR-20-0454. Epub 2020 Apr 24. Clin Cancer Res. 2020. PMID: 32332017
Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study.
Guo C, Chénard-Poirier M, Roda D, de Miguel M, Harris SJ, Candilejo IM, Sriskandarajah P, Xu W, Scaranti M, Constantinidou A, King J, Parmar M, Turner AJ, Carreira S, Riisnaes R, Finneran L, Hall E, Ishikawa Y, Nakai K, Tunariu N, Basu B, Kaiser M, Lopez JS, Minchom A, de Bono JS, Banerji U. Guo C, et al. Lancet Oncol. 2020 Nov;21(11):1478-1488. doi: 10.1016/S1470-2045(20)30464-2. Epub 2020 Oct 28. Lancet Oncol. 2020. PMID: 33128873 Clinical Trial.
59 results